Impax Asset Management Group »

Cytokinetics shares owned by Impax Asset Management Group

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by Impax Asset Management Group from 13F filings

Historical chart of Impax Asset Management Group investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by Impax Asset Management Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by Impax Asset Management Group

Quarter filed Position value Share count Share price at filing
2025-09-30 $9.6M 175k 54.96
2025-06-30 $5.8M 175k 33.04
2025-03-31 $7.0M 175k 40.19
2024-12-31 $8.2M 175k 47.04
2024-09-30 $6.6M 125k 52.80
2024-06-30 $6.8M 125k 54.18

More positions owned by Impax Asset Management Group

Linde Common Stock (LIN)
Microsoft Corp Common Stock (MSFT)
Xylem Common Stock (XYL)
NVIDIA Corp Common Stock (NVDA)
Veralto Corp Common Stock (VLTO)
Hubbell Common Stock (HUBB)
Pentair Common Stock (PNR)
Aptiv Common Stock (APTV)
Agilent Technologies Common Stock (A)
A O Smith Corp Common Stock (AOS)
Advanced Drainage Systems Common Stock (WMS)
IDEX Corp Common Stock (IEX)
RenaissanceRe Holdings Common Stock (RNR)
Synopsys Common Stock (SNPS)
Marvell Technology Common Stock (MRVL)

View all positions for Impax Asset Management Group

Top funds holding Cytokinetics

T. Rowe Price Investment Management
BlackRock
FMR
Vanguard Group
Wellington Management Company
State Street Corporation
Deep Track Capital
Geode Capital Management
Polar Capital Holdings
Rtw Investments
Susquehanna International
Integral Health Asset Management
Armistice Capital
UBS Group
Citadel Advisors

View all funds holding Cytokinetics